Inmune Bio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $50,000 | $14,000 | $155,000 | $374,000 | $181,000 |
| Operating income | -$47.4M | -$42.6M | -$29.7M | -$26.0M | -$29.2M |
| Operating expenses | $47.4M | $42.6M | $29.9M | $26.3M | $29.3M |
| Cash from operations | -$22.6M | -$33.4M | -$12.0M | -$22.7M | -$28.5M |
| Capital expenditure | $1.0M | — | — | — | — |
| Free cash flow | -$23.6M | — | — | — | — |
| Total assets | $32.4M | $39.6M | $57.0M | $81.8M | $99.9M |
| Total liabilities | $8.8M | $7.5M | $18.9M | $21.7M | $19.7M |
| Total debt | — | — | $10.0M | — | — |
Shares outstanding 26.6M · Free float 70.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.